Company Filing History:
Years Active: 1985-1994
Title: The Innovations of David M Sedlock
Introduction
David M Sedlock is a notable inventor based in Bethlehem, NY (US). He has made significant contributions to the field of pharmaceuticals and antimicrobial compositions. With a total of 2 patents, his work focuses on developing innovative solutions for pain management and infection control.
Latest Patents
One of Sedlock's latest patents is titled "Aspergillus species, cyclic dimeric dipeptide derivative substance P." This patent describes a novel Aspergillus species and cyclic dimeric dipeptide derivatives that serve as biosynthetic products. These derivatives are useful as Substance P antagonists, making them valuable as analgesic and anti-inflammatory agents. The patent also outlines a process for preparing these biosynthetic products.
Another significant patent is for "Antimicrobial surface degerming compositions and method of use thereof." This invention includes antimicrobial surface degerming compositions that feature a bis[4-(substituted-amino)-1-pyridinium]alkane, particularly octenidine hydrochloride, as the antimicrobial agent. The compositions also comprise various compounds and an aqueous vehicle, making them suitable for antimicrobial skin cleansing and bovine teat dip applications.
Career Highlights
Throughout his career, David M Sedlock has worked with reputable companies such as Sterling Drug Inc. and Sterling Winthrop Inc. His experience in these organizations has contributed to his expertise in developing innovative pharmaceutical products.
Collaborations
Sedlock has collaborated with notable individuals in his field, including William G Gorman and Karl F Popp. These collaborations have likely enhanced his research and development efforts.
Conclusion
David M Sedlock's contributions to the fields of pharmaceuticals and antimicrobial compositions demonstrate his innovative spirit and dedication to improving health outcomes. His patents reflect a commitment to advancing medical science and addressing critical health challenges.